Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 6/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094220 | 0.80 | LMNA (0.60) | LMNAAVPR2AVPR1A | |
| SCHEMBL13672524 | 0.75 | AVPR1A (0.43) | LMNAAVPR2AVPR1AMAPT | |
| SCHEMBL13672136 | 0.74 | LMNA (0.41) | CNR2LMNAAVPR2AVPR1A | |
| SCHEMBL13672184 | 0.74 | ALDH1A1 (0.46) | LMNAAVPR2AVPR1A | |
| SCHEMBL13672414 | 0.72 | ALDH1A1 (0.42) | LMNAAVPR2AVPR1AMAPT | |
| SCHEMBL13672138 | 0.71 | LMNA (0.46) | CNR2LMNAAVPR2AVPR1ACCR3 | |
| SCHEMBL14218550 | 0.71 | CNR2 (0.45) | CNR2CCR5LMNAMAPK14AVPR2 | |
| SCHEMBL13672519 | 0.71 | ALDH1A1 (0.43) | LMNAAVPR2AVPR1AGAAMAPT | |
| SCHEMBL13672520 | 0.71 | LMNA (0.47) | LMNAAVPR2AVPR1A | |
| SCHEMBL13672183 | 0.69 | ALDH1A1 (0.41) | LMNAAVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | CNR2 1206/4885CCR5 3843/4885LMNA 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.